067 - Diabetes: does it cost a “heart” and a leg? - a podcast by Sean P. Kane, PharmD; Khyati Patel, PharmD

In this episode, we discuss new evidence for cardiovascular outcomes in diabetics based on the LEADER trial (liraglutide) and CANVAS trials (canagliflozin). We also discuss the new FDA warning for canagliflozin regarding amputation risk.

Further episodes of HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast

Further podcasts by Sean P. Kane, PharmD; Khyati Patel, PharmD

Website of Sean P. Kane, PharmD; Khyati Patel, PharmD